Piramal Enterprises Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for PEL, BSE:500302 Piramal Enterprises Ltd.

Piramal Enterprises Ltd.

30 Jul 2019

1170.10

2.19%

Stable quarter; loan growth moderates; asset quality improves sequentially

Buy: Piramal Enterprises Ltd.

Target

Motilal Oswal

Piramal Enterprises (PIEL) reported 1QFY20 PAT of INR4.5b (core PBT up 20% YoY). The quarter was characterized by a moderation in loan growth (flat QoQ and 20% YoY v/s 30%+ earlier), an improvement in asset quality (GNPA flat QoQ; stage 2 loans down to 0.5% from 1.5% in 4Q) and an expansion in the Pharma EBITDA margin to 22% (+200bp YoY). Financial Services: Loan book was stable QoQ at INR566b. Retail housing book grew 18% QoQ to INR61b and accounts for 11% of total loan book (v/s 9% QoQ). Real estate/corp. fin loan book declined 1%/4% QoQ....

Number of FII/FPI investors increased from 251 to 267 in Jun 2025 qtr.

Piramal Enterprises Ltd.

30 Jan 2019

1170.10

2.19%

BP Equities Piramal Enterprises Ltd Q3FY19 Result

Buy: Piramal Enterprises Ltd.

BP Wealth

Piramal Enterprises Ltd. is trading below its 50 day SMA of 1183.9

Piramal Enterprises Ltd.

28 Jan 2019

1170.10

2.19%

Financing business stable, liquidity situation well managed

Buy: Piramal Enterprises Ltd.

Target

Motilal Oswal

Piramal Enterprises (PIEL) 3QFY19 PAT grew 23% YoY to INR6.0b, in keeping with the trend of the past few quarters. Although growth in the Financial Services (FS) business slowed down incrementally, it is commendable against the backdrop of the tough liquidity situation of the 28 January 2019 past quarter. PIEL raised INR100b in the form of term loans and NCDs during the quarter, and also reduced the share of CPs outstanding from 18% to 15% sequentially. Loan book growth moderated to 5% QoQ/45% YoY, which is commendable in this environment. The share of the real estate loan book stands at 69%. PIEL continues scaling up its retail housing loan book well now at close to INR40b. The healthcare business delivered a healthy performance in the quarter, with overall growth of 8% YoY. Growth was largely led by Global Pharma segment (~14% YoY to INR10.6b), partially offset by the muted performance in the India consumer segment.

Number of FII/FPI investors increased from 251 to 267 in Jun 2025 qtr.

Piramal Enterprises Ltd.

15 Nov 2018

1170.10

2.19%

Focus on maintaining liquidity and tracking early warning signals

Buy: Piramal Enterprises Ltd.

Target

Motilal Oswal

14 November 2018 Within a year of launch, PIEL has scaled up its loan book to INR23b, i.e. 4% of total loans. There would be some margin impact on the overall book due to the rising share of home loans. Over the past four quarters, net interest margin for the lending business has declined by 100+bp to 6.9% as the competitive environment has heated up. With the competitive scenario now benign, price wars in the wholesale finance segment have abated. However, Piramal Enterprises PIEL has the distinction of being one of the few companies in India to generate 25%+ book value CAGR over the past 25+ years. We believe the company has the DNA to incubate and grow businesses in niche segments. With a large product suite, huge growth opportunity and a focused team, the overall financial services business will continue to grow at a robust pace and generate 20%+ RoE, in our view.

Number of FII/FPI investors increased from 251 to 267 in Jun 2025 qtr.

Piramal Enterprises Ltd.

18 Sep 2018

1170.10

2.19%

Model Trading Portfolio - Piramal Enterprises Ltd

Buy: Piramal Enterprises Ltd.

Edelweiss

Piramal Enterprises Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 53,501.22...

Piramal Enterprises Ltd. is trading above its 200 day SMA of 1084.2

Piramal Enterprises Ltd.

31 Aug 2018

1170.10

2.19%

Builds up a head of steam in Financial Services

Buy: Piramal Enterprises Ltd.

Target

Motilal Oswal

Piramal Enterprises (PIEL) hosted an analyst meet to discuss its Financial Services business in detail. Management believes that opportunities in corporate lending are aplenty, given that most public sector banks and some private sector banks are not so active in this space. Hence, while bulk of its loan book (~75%) is wholesale real estate lending, management expects the share of non-real estate corporate lending to expand meaningfully over the next three years. Before investing/lending in any segment, the company does a deep study of the sector, which usually takes around six months. To the company's advantage, several...

Piramal Enterprises .. has an average target of 1250.00 from 1 broker.

Piramal Enterprises Ltd.

28 May 2018

1170.10

2.19%

Robust growth on FS business; Profitability lower than expectation

Buy: Piramal Enterprises Ltd.

Target

Motilal Oswal

PBT grew 16% YoY to INR4.7b. However, a DTA benefit (on account of reverse merger of subsidiaries) of INR35b led to PAT of INR39b in the quarter. During the quarter, PIEL merged all its lending subsidiaries into one, namely, Piramal Capital & Housing Finance Ltd. This would help the 28 May 2018 company diversify its borrowing profile, and thus, lower its cost of funds. The loan book continues growing at a rapid pace (+69% YoY to INR422b). With incremental disbursements in relatively safer segments, yield on loans declined 50bp QoQ to 14.8%. Likewise, cost of funds declined 20bp QoQ to 8.4%. RoA, on a QoQ basis, declined 100bp to 3.1% we await clarification from management. Revenue grew 10% YoY to INR13.6b.

Piramal Enterprises Ltd. is trading below its 50 day SMA of 1183.9

Piramal Enterprises Ltd.

31 Jan 2018

1170.10

2.19%

Piramal Enterprises Ltd Q3FY18 results comment

Results Update: Piramal Enterprises Ltd.

HDFC Securities

Piramal Enterprises Ltd Q3FY18 results comment Revenue grew by 12.72% to Rs. 2858.36 Cr in Q3FY18 when compared to the previous quarter

Piramal Enterprises .. has an average target of 1250.00 from 1 broker.

Piramal Enterprises Ltd.

22 Jan 2018

1170.10

2.19%

Piramal Enterprises: Strong growth led by new products

Buy: Piramal Enterprises Ltd.

Target

Motilal Oswal

FY18 is likely to be another strong year for Piramal Enterprises (PIEL). In 1HFY18, the loan book grew ~70% YoY driven by all segments, especially non-real estate corporate financing. The healthcare business too witnessed improving traction. Consolidated PAT was up 28% YoY in 1HFY18. We expect 2HFY18 to be as strong, with 28% PAT YoY growth to INR9.5b. On account of a strong growth outlook for FY19 and FY20 (35% CAGR in our view), PIEL recently raised INR50b via Compulsorily Convertible Debentures (CCDs) and also plans to raise additional INR20b via rights issue, of which the promoters have agreed to underwrite 90%. We believe much of this capital will be used to support growth in the financing business.

Piramal Enterprises Ltd. has gained 32.07% in the last 6 Months

Piramal Enterprises Ltd.

29 Sep 2017

1170.10

2.19%

Piramal Enterprises: Final piece of the jigsaw in place

Buy: Piramal Enterprises Ltd.

Target

Motilal Oswal

Piramal Enterprises (PIEL) hosted a conference call to discuss the launch of its housing finance business. The call revolved around the strategy, competitive positioning and outlook for this segment. Post the receipt of the HFC license in the first week of September, PIEL is off to a good start, driven by its B2B2C' strategy, i.e. reaching out to home buyers in projects...

Piramal Enterprises Ltd. is trading above its 200 day SMA of 1084.2

Is Piramal Enterprises Ltd. worth buying?

796 Votes:

Buy 74.87%

Sell 15.7%

Hold 9.42%

RESEARCH REPORTS

Neutral SEE REPORTS >

pdf

Neutral SEE REPORTS >

pdf